CMS Releases Medicare Drug Price Negotiation Program And Medicare Prescription Drug Benefit Program Final Rule

The Centers for Medicare & Medicaid Services released a final rule, which consists of a permanent framework for negotiating prices for high-cost drugs. By Feb. 1, 2027, CMS will select up to 20 additional negotiation-eligible drugs covered under Part D and/or payable under Part B. The rule also implements a Temporary Floor for Small Biotech Drugs, which is required by law, that prohibits CMS from offering or accepting a counteroffer for an MFP below a specified floor. The Missouri Hospital Association will soon publish an issue brief with additional details.